Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 31

recruiting
3 987
countries
28
conditions
2 109

10 381 trials match your criteria

Non-small cell lung cancer

Recruiting

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Crohn's disease

Recruiting

Study of mirikizumab versus azathioprine in newly diagnosed moderate-to-severe Crohn’s disease patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine

Colitis ulcerative+2

Recruiting

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab

Oesophageal adenocarcinoma

Recruiting

Study of denikitug alone or with drug combination in adults with HER2‑negative metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Lupus nephritis

Recruiting

Safety and early efficacy of TranspoCART19 CAR‑T CD19 therapy in patients with refractory lupus nephritis (Phase I‑IIa)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Transpocart19

Pneumonia bacterial

Recruiting

Rifabutin plus drug combination for adult patients with hospital‑acquired and ventilator‑associated pneumonia caused by carbapenem‑resistant Acinetobacter baumannii

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Ampicillin Sodium

Acute myeloid leukaemia

Recruiting

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine

Rheumatoid arthritis

Recruiting

Discontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab

Plasma cell myeloma

Recruiting

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Malignant mast cell neoplasm

Recruiting

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Follicular lymphoma

Recruiting

Study of MK-1045 plus rituximab in patients with newly diagnosed follicular lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Measles+3

Recruiting

Long‑term immunity after a 6‑month‑old MMR vaccine (live attenuated) in infants: follow‑up of antibody levels 1‑3 years after routine vaccination

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · Healthy volunteers
  • Substances:MUMPS VIRUS RIT 4385 STRAIN (LIVE, ATTENUATED) DERIVED FROM FROM THE JERYL LYNN PRODUCED IN CHICK EMBRYO CELLS

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.